Showing results (151-160 of 390) with videos related to
Sort By:
Pageof 39
Neurology|December 8, 2017
Diet quality is associated with disability and symptom severity in multiple sclerosisKathryn C Fitzgerald, Tuula Tyry, Amber Salter, et al.JAMA Neurology|September 3, 2014
The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosisJeffrey A Cohen, Arun V Krishnan, Andrew D Goodman, et al.Annals of the New York Academy of Sciences|January 3, 2013
Biomarker development for myasthenia gravisHenry J Kaminski, Linda L Kusner, Gil I Wolfe, et al.American Journal of Physiology. Renal Physiology|September 20, 2014
Distinct populations of label-retaining cells in the adult kidney are defined temporally and exhibit divergent regional distributionsSunil Rangarajan, Bhuvana Sunil, Chunlan Fan, et al.Neurology|August 11, 2021
Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease SpectrumMarcus W Koch, Jop Mostert, Yinan Zhang, et al.Journal of Neuroimmunology|September 11, 2003
Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progressionIoana R Moldovan, Richard A Rudick, Anne C Cotleur, et al.Proceedings of the National Academy of Sciences of the United States of America|November 23, 2011
The role of cell type-specific responses in IFN-β therapy of multiple sclerosisJoana A Zula, Holly C Green, Richard M Ransohoff, et al.Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|September 27, 2024
Prevalence of restless legs and association with patient-reported outcome measures in myasthenia gravisMohanad AlGaeed, Tarrant McPherson, Ikjae Lee, et al.Epilepsy & Behavior : E&B|July 17, 2021
Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsyLeslie Grayson, Steve Ampah, Kathleen Hernando, et al.Journal of Neurology|May 15, 2022
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial datasetMarcus W Koch, Jop Mostert, Pavle Repovic, et al.Pageof 39